Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
Background: Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated i...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
BioMed Central
2018
|
Subjects: |